Zynerba Pharmaceuticals (ZYNE) stock is down -37.8% over the past 30 days. ZYNE stock has gained 56.77% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. Stock Score Report, InvestorsObserver’s proprietary scoring system, gives ZYNE stock a score of 57 out of a possible 100.
That score is primarily influenced by a fundamental score of 81. In addition to the average rating from Wall Street analysts, ZYNE stock has a mean target price of $22.50. This means analysts expect the stock to rise 134.13% over the next 12 months. ZYNE’s score also includes a short-term technical score of 48. The long-term technical score for ZYNE is 42.
What’s Happening with ZYNE Stock Today
Zynerba Pharmaceuticals Inc (ZYNE) stock is lower by -5.45% while the S&P 500 has fallen -2.31% as of 12:15 PM on Monday, Aug 5. ZYNE has fallen -$0.55 from the previous closing price of $10.16 on volume of 600,367 shares. Over the past year the S&P 500 is higher by 0.48% while ZYNE has gained 56.77%. ZYNE lost -$2.61 per share in the over the last 12 months.